BridgeMD
Tests treatment safety and results for Lupus Nephritis (LN)
Official title The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis Population
ClinicalTrials.gov ID: NCT07700940
What this study is testing
What is Empagliflozin (25 Mg Tab) along with standard medical therapy?
Empagliflozin (25 Mg Tab) along with standard medical therapy is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for lupus nephritis (ln).
Also referred to as EMPA, SGLT2Is.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Systemic lupus erythematosis (SLE) is a chronic, most probably auto-immune multisystem disease marked by relapsing-remitting course and the formation of a range of autoantibodies. SLE patients present with serious renal (lupus nephritis (LN)), cardiopulmonary, or nervous manifestation.
- Phase 4: studies an already-approved treatment
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Adults (≥ 18 years) with established biopsy-proven LN of active III, IV, overlapping III/IV, or overlapping III/V classes.
- eGFR ≥ 30 ml.min1.1.73m-2,
- Urinary protein creatinine ratio (uPCR) \> 1000 mg/g.
You likely can't join if
- people with serious hypersensitivity (angioedema and/or anaphylaxis) to EMPA.
- eGFR \< 30 ml.min-1.1.73m-2.
- uPCR \< 1000 mg/g.
- Type 1 or 2 diabetes.
- Aterial fibrillation.
- Hepatic impairment [defined as alanine transaminase or aspartate transaminase \>3 times the upper limit of normal (ULN) or total bilirubin \>2 times...
See the full eligibility criteria
- Adults (≥ 18 years) with established biopsy-proven LN of active III, IV, overlapping III/IV, or overlapping III/V classes.
- eGFR ≥ 30 ml.min1.1.73m-2,
- Urinary protein creatinine ratio (uPCR) \> 1000 mg/g.
- people with serious hypersensitivity (angioedema and/or anaphylaxis) to EMPA.
- eGFR \< 30 ml.min-1.1.73m-2.
- uPCR \< 1000 mg/g.
- Type 1 or 2 diabetes.
- Aterial fibrillation.
- Hepatic impairment [defined as alanine transaminase or aspartate transaminase \>3 times the upper limit of normal (ULN) or total bilirubin \>2 times the ULN at the time of enrolment].
- Any condition outside the renal and cardiovascular study area with a life expectancy of \< 6 months based on care provider's clinical judgment.
- Those who enrolled in an experimental study in the previous 6 months.
The study team makes the final eligibility decision.
Where it's taking place
- Banī Suwayf, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Banī Suwayf, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.